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Polygenic risk scores (PRS) have been shown to predict breast cancer risk in European
women, but their utility in Asian women is unclear. Here we evaluate the best performing
PRSs for European-ancestry women using data from 17,262 breast cancer cases and 17,695
controls of Asian ancestry from 13 case-control studies, and 10,255 Chinese women from a
prospective cohort (413 incident breast cancers). Compared to women in the middle quintile
of the risk distribution, women in the highest 1% of PRS distribution have a ~2.7-fold risk and
women in the lowest 1% of PRS distribution has ~0.4-fold risk of developing breast cancer.
There is no evidence of heterogeneity in PRS performance in Chinese, Malay and Indian
women. A PRS developed for European-ancestry women is also predictive of breast cancer
risk in Asian women and can help in developing risk-stratified screening programmes in Asia.
https://doi.org/10.1038/s41467-020-17680-w OPEN
#A list of authors and their affiliations appears at the end of the paper.
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In the majority of high-income Western countries, breastcancer screening is systematic and population-based, and thishas contributed to an improvement in survival1. By contrast,
screening in the majority of Asian countries is opportunistic and
suffers from poor uptake, contributing to delayed detection and
poor survival2. In addition, there are concerns about the appro-
priate starting age of screening, as women are recommended to
start screening at age 50 in many Asian countries, even though
the peak breast cancer incidence in Asian populations is between
40 and 50 years of age3. Taken together with the rapidly
increasing incidence of breast cancer in Asia4, there is thus an
urgent need to develop an appropriate screening strategy for
Asian women.
Provision of genetic counselling and genetic testing for rare
variants in breast cancer predisposition genes such as BRCA1 and
BRCA2 can lead to better management of risk, but these only
explain a small fraction of breast cancer cases in the general
population5. Risk profiles based on a combination of low pene-
trance but common breast cancer susceptibility single nucleotide
polymorphisms (SNPs), summarised as polygenic risk scores
(PRS), have been shown to be an important predictor of disease
risk6–8. A 313-SNP PRS developed in European populations has
improved predictive power compared to earlier PRS based on
fewer SNPs;6,7 this PRS demonstrated similar associations with
disease risk in eleven independent prospective studies. Studies in
European populations have demonstrated that PRS substantially
improve discrimination, in comparison to risk prediction models
based on classical risk factors alone8,9. In particular, using
the recent extension of the BOADICEA model, it has been
demonstrated that the 313-SNP PRS provides greater level of
risk stratification in the population than epidemiological risk
factors alone, and that the greatest level of risk stratification is
achieved when both the PRS and epidemiological risk factors
are considered jointly10. Screening trials11–13 in women of pre-
dominantly European descent are ongoing to evaluate persona-
lised breast cancer screening programme based on a woman’s
individual risk of disease, as a means of improving screening
efficiency14.
Although there have been several efforts to create an Asian-
specific PRS, these have been limited by the smaller sample size of
Asian genetic studies15–19. Only ~20% of the existing breast
cancer genome-wide association study (GWAS) data are from
women of Asian ancestry20,21. This limits the precision in the
relative risk estimates for individual variants, which is critical for
development of predictive PRS. Furthermore, Asian populations
are ethnically and genetically diverse22, and genetic associations
with breast cancer risk may vary by ancestry. Here, we evaluate
the predictive ability of the 313-SNP PRS developed for European
women for predicting breast cancer risk in Asian women, using
data from 17,262 cases and 17,695 control women of Asian
ancestry, from 10 studies based in Asian countries and three
studies from North America, participating in the Breast Cancer
Association Consortium (BCAC); and 10,255 Chinese women
from a prospective cohort. We also evaluate the heterogeneity in
the associations with breast cancer risk by ethnicity. We show
that European ancestry-based PRS is predictive of breast cancer
risk in Asian women.
Results
SNPs included in PRS analyses. To ensure accurate determina-
tion of PRS in the ethnic-specific analyses, 26 of the 313 SNPs
with imputation accuracy scores <0.9, based in the Malaysian
Breast Cancer Genetic Study (MyBrCa) and Singapore Breast
Cancer Cohort (SGBCC) of 6900 cases and 7606 controls, com-
bined, were excluded. Hence, the PRS was constructed using 287
SNPs for all BCAC studies (Supplementary Table 1). For the
Singapore Chinese Health Study (SCHS), 229 of the 287 SNPs
that were polymorphic and could be imputed in this dataset were
used for PRS derivation. To compare the PRS performance with
that in women of European ancestry, we recalculated the PRS
using these sets of SNPs in the validation and prospective cohorts
of European women described in Mavaddat et al.7.
For association analyses between PRS and overall breast cancer,
the PRS was calculated using overall breast cancer weights while
for association analyses between PRS and subtype-specific breast
cancer, subtype-specific PRSs were constructed using the same set
of SNPs but weights from the hybrid method described by
Mavaddat et al.7 [see section “Methods”]. The list of SNPs and
corresponding weights used to construct the 287-SNP PRS and
229-SNP PRS are provided in Supplementary Data 1.
PRS and breast cancer risk in Asian women living in Asia. Data
on 15,755 invasive cases and 16,483 control women from 10
Asian studies in BCAC were included (Supplementary Table 1).
The mean of the 287-SNP PRS was markedly higher in Asian
women compared to European women for overall breast cancer
PRS (PRSOVERALL), ER-positive PRS (PRSER+) and ER-negative
PRS (PRSER−), while the standard deviations (SDs) were slightly
lower in Asian controls [versus European controls] for all three
PRSs (0.556 [0.597], 0.592 [0.638] and 0.533 [0.567], respectively,
Table 1). The remaining analyses for 287-SNP PRSs in this
manuscript are presented in terms of the PRS standardised to the
SD in the European controls.
Table 2 shows the estimated odds ratio (OR) per unit increase
of standardised PRSs for overall and subtype-specific breast
cancer. For overall breast cancer, the estimated OR per SD was
1.52 (95% confidence interval (CI): 1.49–1.56). For subtype-
specific disease, the estimated OR per SD of the subtype-specific
PRS was 1.62 (95% CI: 1.57–1.67) for ER-positive and 1.41 (95%
CI: 1.36–1.46) for ER-negative disease. There was no evidence of
heterogeneity among studies genotyped with either the iCOGS or
OncoArray (p values for heterogeneity >0.05 [chi-squared test],
Fig. 1). For overall breast cancer and ER-positive disease, the ORs
per SD of the PRS were slightly higher in OncoArray genotyped
studies compared to the studies genotyped with iCOGS. However,
the confidence intervals for the array-specific estimates over-
lapped (Fig. 1). There was no evidence that the effect of PRS was
modified by age (p value of interaction < 0.05 [Student’s t test];
Supplementary Table 2). When analyses were stratified by 10-year
age groups, the ORs per SD of the PRS by age group were similar
(Supplementary Table 3).
The association between the PRSs and breast cancer risk by
PRS percentile are shown in Fig. 2 and Supplementary Table 4.
Compared to women in the middle quintile (40–60%), the
observed OR of developing overall breast cancer for women in the
highest and lowest 1% of the PRS distribution was 2.72 (95% CI:
2.24–3.29) and 0.38 (95% CI: 0.27–0.52), respectively. Women in
the highest and lowest 1% of the ER-specific PRSs had 2.84 (95%
CI: 2.30–3.49)- and 0.25 (95% CI: 0.16–0.39)-fold risk, respec-
tively, for ER-positive disease, and 2.29 (95% CI: 1.77–2.97)- and
0.57 (95% CI: 0.36–0.90)-fold risk, respectively, for ER-negative
disease. The observed ORs by PRS percentile did not differ from
those predicted under a theoretical polygenic model in which the
log OR depends-linearly on the PRS: all predicted ORs fall within
the confidence intervals of the observed ORs (Fig. 2; Supplemen-
tary Table 4).
Table 3 shows the association between family history of breast
cancer and overall/ER-specific breast cancer risk, adjusted and
unadjusted for standardised overall/ER-specific PRSs. Family
history information was not available for all cases in Seoul Breast
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Cancer Study (genotyped on OncoArray) or control women in
the second batch of Singapore Breast Cancer Cohort, hence both
studies were excluded from these analyses. The percentage
attenuation in the log ORs for family history after adjusting for
PRSs was 10.0% for overall breast cancer (unadjusted family
history OR= 1.35, adjusted OR= 1.31), 7.3% for ER-positive
breast cancer (unadjusted OR= 1.36, adjusted OR= 1.33) and
13.2% for ER-negative breast cancer (unadjusted OR= 1.2,
adjusted OR= 1.18). There was no evidence of interaction
between the PRSs and family history (p values ≥ 0.05 [Student’s
t test], Supplementary Table 2). Including family history in the
model, in addition to the PRS, increased the AUC only slightly
(0.616 vs. 0.613 for PRS alone; Table 2).
PRS and breast cancer risk in Chinese, Malays and Indians.
Analyses by ethnic subgroup were limited to 6900 invasive cases
and 7506 controls participating in MyBrCa and SGBCC studies
(Supplementary Table 1). Malaysia and Singapore are ethnically
diverse, with the majority of individuals identifying as Chinese,
Malay or Indian. Principal component analysis showed that these
ethnic groups can be distinguished based on genetic data; how-
ever, the distribution of the first two principal components for
each ethnic group was similar between the two countries (Sup-
plementary Fig. 1). Hence for the purposes of this analysis,
women belonging to the same ethnic group from the two coun-
tries were analysed together.
Table 4 summarises the characteristics of the study participants
by self-reported ethnicity. The majority of the participants were
Chinese (72%), while 17% and 11% were Malay and Indian,
respectively. The mean PRS was markedly higher in Chinese and
Malay women compared to European women, with the mean
being highest for Chinese women. The mean for Indian women
was intermediate between those for Chinese and Malay women
Table 2 Association between standardised polygenic risk scores and breast cancer risk.
287-SNP PRS 287-SNP PRS 229-SNP PRS 229-SNP PRS
Cases, N Controls, N OR per SDa (95% CI) AUC OR per SDa (95% CI) AUC
Asian studies in BCAC
Overall BC 15,755 16,483 1.52 (1.49–1.56) 0.613 1.49 (1.45–1.52) 0.611
ER-positive 10,477 16,483 1.62 (1.57–1.67) 0.627
ER-negative 4,764 16,483 1.41 (1.36–1.46) 0.594
Asians within North American
Studies in BCAC
Overall BC 1507 1212 1.36 (1.25–1.49) 0.577 1.33 (1.22–1.45) 0.579
ER-positive 1022 1212 1.38 (1.25–1.53) 0.586
ER-negative 280 1212 1.49 (1.26–1.76) 0.587
Prospective cohort
Overall BC 413 9842 1.49 (1.33–1.67) 0.61
European studies
Overall BC 11,225 17,788 1.61 (1.57–1.66) 0.630 1.59 (1.55–1.64) 0.627
ER-positive 7809 17,788 1.68 (1.64–1.73) 0.642
ER-negative 1234 17,788 1.44 (1.36–1.53) 0.600
aAdjusted for first ten principal components and study, and standardised to SDs of PRSs in European controls as shown in Table 1. For prospective cohort, model was adjusted for first seven principal
components. Only 229 of the 287 SNPs that were polymorphic and could be imputed were available for the prospective cohort. To enable comparison between case-control studies and prospective
cohort, we included the results of 229-SNP PRS for all studies. For studies in Breast Cancer Association Consortium (BCAC), AUCs were adjusted by study. The OR per SD and AUC for European studies
were estimated using the same data on the prospective cohorts as described in Mavaddat et al.7. PRS polygenic risk scores.
Table 1 Mean and standard deviation of 287-SNP and 229-SNP polygenic risk scores.
Mean PRS (SD) Mean PRS (SD) Mean PRS (SD) Mean PRS (SD)
287-SNP PRS 287-SNP PRS 229-SNP PRS 229-SNP PRS
Cases, N Controls, N Cases Control Cases Control
Asian studies in BCAC
PRSOVERALL 15,755 16,483 0.91 (0.554) 0.69 (0.556) 1.09 (0.537) 0.88 (0.539)
PRSER+ 10,477 16,483 0.89 (0.580) 0.62 (0.592)
PRSER− 4764 16,483 1.26 (0.543) 1.07 (0.533)
Asian within American studies
in BCAC
PRSOVERALL 1507 1212 0.91 (0.560) 0.75 (0.546) 1.09 (0.545) 0.93 (0.529)
PRSER+ 1022 1212 0.89 (0.598) 0.69 (0.583)
PRSER− 280 1212 1.27 (0.513) 1.12 (0.512)
Prospective cohort
PRSOVERALL 413 9842 1.06 (0.539) 0.85 (0.523)
European studies
PRSOVERALL 5129 5285 0.44 (0.608) 0.12 (0.597) 0.72 (0.608) 0.435 (0.556)
PRSER+ 4233 5285 0.43 (0.651) 0.05 (0.638)
PRSER− 926 5285 0.78 (0.560) 0.54 (0.567)
The overall breast cancer (BC) PRS (PRSoverall) and oestrogen-receptor (ER)-positive PRS (PRSER+) and ER-negative PRS (PRSER−) were derived as describe in the “Method” section. ER-subtype is not
available for the prospective cohort. Mean and SD of PRS in European studies were calculated using the data on the validation set as described in Mavaddat et. al.7 but samples with missing ages
information were removed. BCAC Breast Cancer Association consortium, SD standard deviation, PRS polygenic risk scores.
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and those for European women (Tables 1 and 4). The PRS SDs of
Malay and Indian controls were similar to that of women of
European ancestry, while Chinese’s SDs were slightly lower.
The breast cancer OR per SD of the 287-SNP PRSs and
the discriminatory accuracy, measured by area under the
receiver operating characteristic curve (AUC), was similar
across the three ethnic groups (heterogeneity p values > 0.05
[chi-squared test]; AUCs for overall breast cancer were
0.60–0.62, for ER-positive disease were 0.62–0.63 and for ER-
negative disease were 0.57–0.60; Fig. 3). OR estimates by
percentiles for overall breast cancer risk, compared to the
middle quintile are shown in Fig. 4 and Supplementary Table 5.
The OR estimates were similar across ethnicities, except that for
the highest 10% of the PRS distribution, where Chinese had
a higher OR (2.19, 95% CI: 1.91–2.52) compared to Malays
(1.79 95% CI: 1.35–2.37) and Indians (1.57, 95% CI: 1.09–2.26).
a
b
Study OR (95%CI)
Study
Asian studies
ACP
HERPACC
HKBCS
KOHBRA
MYBRCA batch 1
MYBRCA batch 2
NGOBCS
SBCGS
SEBCS
SGBCC batch 1
SGBCC batch 2
TWBCS
Combined
American studies
CBCS
NC-BCFR
Combined
(I-squared = 16.23%, p = 0.2848)
(I-squared = 0%, p = 0.4190)
OR (95%CI)
1.32 (1.15–1.52)
OR (95%CI) OR (95%CI)
1.05 (0.85–1.29)
1.96 (1.28–2.99)
1.25 (1.03–1.52)
1.45 (1.27–1.66)
1.39 (1.20–1.61)
1.40 (1.27–1.53)
1.33 (1.02–1.72)
1.70 (1.46–1.99)
1.42 (1.26–1.61)
1.53 (1.28–1.84)
1.38 (1.26–1.51)
1.47 (1.18–1.84)
1.41 (1.35–1.47)
 (l-squared = 42.09%, p = 0.0612)
1.38 (0.88–2.17)
1.29 (0.86–1.94)
1.33 (0.99–1.8)
(l-squared = 0%, p = 0.8309)
1.54 (1.30–1.81)
1.68 (1.33–2.12)
1.54 (1.31–1.81)
1.70 (1.51–1.92)
1.75 (1.55–1.98)
1.58 (1.47–1.71)
1.53 (1.29–1.81)
1.68 (1.48–1.91)
1.74 (1.55–1.94)
1.62 (1.42–1.86)
1.68 (1.58–1.79)
1.52 (1.26–1.84)
1.65 (1.59–1.70)
(I-squared = 0%, p = 0.8518)
1.18 (0.94–1.48)
1.59 (1.14–2.21)
1.29 (1.07–1.56)
(I-squared = 52.9%, p = 0.1451)
1.71 (1.37–2.13)
1.41 (1.22–1.62)
1.62 (1.46–1.81)
1.61 (1.45–1.79)
1.49 (1.40–1.60)
1.40 (1.20–1.64)
1.64 (1.47–1.83)
1.59 (1.45–1.75)
1.59 (1.41–1.79)
1.56 (1.48–1.66)
1.57 (1.32–1.87)
1.55 (1.50–1.59)
1.18 (0.96–1.47)
1.38 (1.02–1.87)
1.25 (1.05–1.49)
ER-positive
ER-positive
ER-negative
ER-negative
Overall
Overall
1.25 (1.08–1.44)
1.52 (1.36–1.70)
1.46 (1.31–1.62)
1.55 (1.40–1.71)
1.44 (1.22–1.70)
1.46 (1.39–1.54)
1.41 (1.27–1.56)
0.90 1.0 2.5
Odds ratios
0.90 1.0 2.5
Odds ratios
0.90 1.0 2.5
Odds ratios
0.90 1.0 2.5
Odds ratios
0.90 1.0 2.5
Odds ratios
0.90 1.0 2.5
Odds ratios
(I-squared = 37.29%, p = 0.1726)
OR (95%CI) OR (95%CI)
1.18 (0.88–1.56)
1.60 (1.40–1.83)
1.42 (1.26–1.61)
1.69 (1.50–1.91)
1.43 (1.19–1.72)
1.53 (1.43–1.63)
1.42 (1.26–1.60)
(I-squared = 51.55%, p = 0.0826)
1.16 (0.82–1.62)
1.37 (1.12–1.68)
1.55 (1.32–1.81)
1.38 (1.21–1.58)
1.30 (1.05–1.615)
1.39 (1.29–1.51)
1.59 (1.30–1.95)
(I-squared = 0%, p = 0.5030)
Asian studies
ACP
HERPACC
SBCGS
SEBCS
TWBCS
Combined
American studies
LAABC
Fig. 1 Association between standardised 287-SNP polygenic risk scores and breast cancer risk. Panel a shows the results for iCogs array by study and
panel b shows the results for Oncoarray. The squares represent the odds ratios (ORs) and the horizontal lines represent the corresponding 95%
confidence intervals. Overall estimates within genotyping array were obtained by combining the estimates across studies using fixed-effect meta-analysis,
represented by the diamond shape. I-squared and p value (two-sided) for heterogeneity were obtained by fitting a random-effects model and using
generalised Q-statistic estimator (the rma() command in R). The sample size of individual studies are listed in Supplementary Table 1. The ORs and
corresponding 95% confidence intervals are provided as a Source Data file.
Overall breast cancer
4.0
1.0
O
dd
 ra
tio
s
0.1
<1%
1–5%
5–10%
10–20%
20–40%
40–60%
60–80%
80–90%
90–95%
95–99%
>99%
<1%
1–5%
5–10%
10–20%
20–40%
40–60%
60–80%
80–90%
90–95%
95–99%
>99%
<1%
1–5%
5–10%
10–20%
20–40%
40–60%
60–80%
80–90%
90–95%
95–99%
>99%
4.0
1.0
O
dd
 ra
tio
s
0.1
4.0
1.0
O
dd
 ra
tio
s
0.1
a b c
ER-positive breast cancer ER-negative breast cancer
Fig. 2 Association between percentiles of 287-SNP polygenic risk scores (PRS) and breast cancer risk in combined Asian studies. The results for
overall breast cancer, oestrogen-receptor (ER)-positive breast cancer and ER-negative breast cancer are shown in Fig. 2a–c, respectively. The squares/dots
represent the odds ratios (ORs) and the vertical lines represent the corresponding 95% confidence intervals, with middle quintile (40–60th) as the
reference category. Solid lines represent the observed ORs, black dashed lines represent the predicted ORs of PRSs under a multiplicative polygenic model
in the Asian population and the red dashed line represent the predicted OR in the European population. The analysis was conducted using 15,755 cases and
16,438 controls. Of 15,755 cases, 9989 were ER-positive breast cancer while 4611 were ER-negative breast cancer. Source data are provided in
Supplementary Table 5.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-17680-w
4 NATURE COMMUNICATIONS |         (2020) 11:3833 | https://doi.org/10.1038/s41467-020-17680-w |www.nature.com/naturecommunications
However, the confidence intervals of the ethnicity-specific
estimates overlapped (Fig. 4).
PRS and breast cancer risk in Asian Americans. The 287-SNP
PRS was also evaluated using data from 2719 women of Asian
ancestry recruited into three studies from North America (Sup-
plementary Table 1). The means for all PRS were very similar to
those in the Asian studies, and markedly higher than those in
Europeans. The SDs in controls for all PRSs were similar to those
in the Asian studies and somewhat lower than the observed SDs
in European controls (Table 1).
Compared to the breast cancer OR per SD in the Asian studies
from Asia, the OR per SD of the 287-SNP PRS in the North
American studies was smaller (p < 0.05) for overall breast cancer
(1.36, 95% CI: 1.25–1.49) and ER-positive breast cancer
(1.38, 95% CI: 1.25–1.53), but higher (p < 0.05) for ER-negative
breast cancer (1.49, 95% CI: 1.26–1.76, Table 2). Of the three
studies included in these analyses, only the Los Angeles County
Asian–American Breast Cancer (LAABC) case–control study
showed a significant association with breast cancer risk for
all three PRSs while the Canadian Breast Cancer (CBC) study
showed non-significant association across all PRSs (Fig. 1).
However, the heterogeneity in the estimates among studies was
not significant.
Prospective evaluation for PRS. We further evaluated the PRS in
the prospective Singapore Chinese Health Study (SCHS), using
data on 10,255 women, of whom 413 had developed breast cancer
(Supplementary Table 1). The mean and SD of the 229-SNP PRS
in the prospective study were similar to the mean and SD of 229-
SNP PRS in the BCAC Asian studies (Table 1). The estimated
hazard ratio (HR) for overall breast cancer, per European-SD of
the 229-SNP PRS, was 1.49 (95% CI: 1.33–1.67) and the AUC
was 0.610 (Table 2). The estimates were similar to those for the
229-SNP PRS in Asian studies (Asian studies from Asia:
1.49 (1.45–1.52); from North American studies: 1.33 (1.22–1.45))
but slightly lower than those in the European studies (1.59
(1.55–1.64)).
Absolute risk of developing breast cancer by PRS percentiles.
Absolute lifetime and 10-year breast cancer risks by 287 SNP PRS
percentile were derived by combining the estimated overall breast
cancer ORs from BCAC Asian studies (Supplementary Table 4)
and the breast cancer incidence and mortality rates for Chinese,
Malay and Indian women in Singapore23,24 (Table 5; Supple-
mentary Fig. 2). The risks of developing breast cancer by age 80
for women in the lowest and highest 1% of the PRS distribution
were ~2% and ~13–16%, respectively, depending on ethnicity. For
women between the 90 and 99th percentiles of the risk dis-
tribution, the lifetime risks vary from 9 to 13%. Assuming that
a 10-year absolute risk threshold of 2.3% (approximately the 10-
year risk from age 50 in women of European descent25) is used to
define women at sufficient risk to justify screening, Chinese and
Malay women in the highest 1% of the PRS distribution would
reach this threshold by age 35, while Indian women in the highest
1% would reach the threshold at age 39 years.
We also determined the proportion of women in the general
population who would have 10-year absolute risk above the risk
threshold (2.3%) at some point in their life. The maximum 10-year
absolute risk for Chinese women in the highest 25%, Malay women
in the highest 16% and Indian women in the highest 17% of the
PRS distribution were greater than 2.3%. Offering screening to these
women would capture ~40%, ~27% and ~28% of all breast cancer
cases in the Chinese, Malay and Indian populations, respectively
(Supplementary Fig. 3).
Comparison with other PRSs. We compared the predictive
performance of the 287-SNP PRS for overall breast cancer with
five PRSs15,17,19,26,27, which were previously developed or eval-
uated using data from Asian populations. Of these 5 PRSs, one
was developed using iCogs genotyped studies in BCAC and
744 samples from MyBrCa study15. To avoid the potential of
overfitting and to enable direct comparison between PRSs, we
limited the analyses to OncoArray genotyped studies only
(excluding 744 samples from MyBrCa study). We also recalculate
the 287-SNP PRS using the same samples. The list of SNPs and
corresponding weights as reported in the literature are given in
Supplementary Table 6. The ORs per one SD of the 5 Asian PRSs
Table 4 Characteristics of women in Malaysian Breast Cancer Genetic Study and Singapore Breast Cancer Cohort.
Chinese Cases Chinese Controls Malay Cases Malay Controls Indian Cases Indian Controls
N
Overall BC 5236 5156 1084 1332 580 1018
ER-positive 3627 5156 715 1332 374 1018
ER-negative 1365 5156 336 1332 184 1018
Age, years, mean (SD) 53.1 (10.93) 51.8 (9.73) 49.7 (10.18) 51.1 (8.73) 53.2 (10.53) 54.1 (8.75)
Polygenic risk score,
mean (SD)
PRSoverall 0.91 (0.54) 0.69 (0.54) 0.85 (0.58) 0.63 (0.58) 0.56 (0.57) 0.33 (0.61)
PRSER+ 0.89 (0.57) 0.63 (0.58) 0.84 (0.59) 0.57 (0.62) 0.55 (0.57) 0.26 (0.65)
PRSER− 1.24 (0.53) 1.07 (0.52) 1.11 (0.55) 0.98 (0.55) 0.92 (0.57) 0.75 (0.55)
N is the number of samples for cases and control in each subtype and ethnicity. Age is age of consent for controls and age of cancer diagnosis for cases. Mean and SD of age of cancer diagnosis were
calculated using overall breast cancer (BC) cases. PRS was computed based on 287 SNPs. Mean and SD of PRSoverall, PRSER+ and PRSER− in cases were calculated using all cases, ER-positive cases and
ER-negative cases, respectively. Self-declared ethnicity was used.
Table 3 First-degree family history of breast cancer and
breast cancer risk in Asian studies.
Unadjusted for
PRS, OR*
(95% CI)
Adjusted for
PRS, OR
(95% CI)
Attenuation
(%)a
Overall BC 1.35 (1.22–1.48) 1.31 (1.18–1.45) 10.0
ER-positive 1.36 (1.22–1.53) 1.33 (1.19–1.49) 7.3
ER-negative 1.21 (1.05–1.39) 1.18 (1.03–1.37) 13.2
PRS was computed based on 287 SNPs. *Odds ratio for developing breast cancer for women
with a family history of breast cancer in a first-degree relative compared with women without a
family history, adjusted for study and 10 principal components. All the case–control studies
listed in Supplementary Table 1 were included in this analysis, except for SEBCS and SGBCC
Batch 2. Family history information was not available for all cases in SEBCS (genotyped on
Oncoarray) and all controls for SGBCC Batch 2 hence excluded from the analyses.
aPercent attenuation on log scale.
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were between 1.10 and 1.41 and corresponding AUCs were
between 0.533 and 0.586, substantially lower than that for the
European-ancestry based 287-SNP PRS (Table 6).
Discussion
To date, the utility of incorporating common genetic variants into
breast cancer risk prediction models has predominantly been
investigated in women of European descent. Previous efforts in
Asian studies thus far have focused on the development of Asian-
specific PRS, and have been limited by small sample size. Given
the difficulties of defining population-specific PRS, a more
practical question is whether the PRS developed using data from
women of European ancestry is predictive of risk for women of
Asian ancestry. In this study, using the largest available data of
Asian women, we independently evaluated the predictive per-
formance of PRS developed based on 287 variants.
Our study showed that the European-ancestry PRS was pre-
dictive of overall breast cancer risk for Asians. The magnitudes of
association were generally consistent across the ten participating
case–control Asian studies and the prospective Singaporean
Chinese study. The association was also consistent across the
three ethnic groups in Malaysia and Singapore, suggesting that
the PRS is associated with similar relative risk estimates in all
three ethnicities, though the confidence intervals for Malays and
Indians are wide.
The estimated effect size and AUC of both the 287-SNP PRS
and 229-SNP PRS were slightly lower than that observed in
women of European ancestry. We evaluated the individual
association of the 287 SNPs with overall breast cancer risk in
Chinese, Malays and Indians separately and compared with the
effect sizes in women of European ancestry (Supplementary
Data 1). The intraclass correlation coefficients (ICC), taking into
account standard errors of estimates, was estimated to be >0.7 for
all ethnicities. These results indicate that the susceptibility var-
iants in both populations are largely similar and confer similar
relative risks, the lower effect size and AUC may arise from dif-
ferent patterns of linkage disequilibrium. Notably, our analyses
showed that the Asian-specific PRS which included only five
Asian-specific SNPs27, achieved AUC of 0.562 (Table 6), sug-
gesting the development of more accurate PRSs in the Asian
population is possible when larger cohorts of Asians becomes
available to identify population-specifc SNPs.
The mean for the 287-SNP PRS was markedly higher in Asian
populations than European populations, but the SD was slightly
lower in Asians than Europeans. The lower variation (SD) may
reflect the different allele frequency distributions: of the 287 SNPs
that are common in women of European ancestry (minor allele
frequency > 0.05), 43 are rare in Asian women and therefore
contribute minimally to the PRS. In this paper, we have stan-
dardised the PRS to the European SD to enable comparison of the
performance of the PRS in European and Asian populations.
A more relevant approach is to standardised the PRS to the Asian
SD, in which case the overall breast cancer OR per unit
increase in PRS would be decreased to 1.48 (95% CI: 1.44–1.52).
Taken together, these results highlight the need to calibrate the
PRS distribution to enable risk models developed based on
one population (e.g. Europeans) to be used in another population
(e.g. Asians).
Overall breast cancer OR per SD (95%CI)
1.58 (1.51–1.65)
AUC (95%CI)
0.62 (0.60–0.63)
0.60 (0.58–0.60)
0.61 (0.59–0.64)
0.63 (0.61–0.64)
0.62 (0.60–0.65)
0.63 (0.60–0.67)
0.60 (0.58–0.61)
0.57 (0.53–0.60)
0.59 (0.54–0.63)
1.48 (1.36–1.62)
1.48 (1.33–1.65)
1.55 (1.5–1.61)
1.61 (1.54–5.42)
1.57 (1.43–5.58)
1.55 (1.38–5.70)
1.59 (1.53–1.66)
1.48 (1.38–1.59)
1.30 (1.14–1.49)
1.38 (1.16–1.64)
1.43 (1.35–1.52)
1.0
Odds ratios
ER-positive
Chinese
Malay
Indian
Chinese
Malay
Indian
Combined (I-squared = 18.28%, p = 0.2942)
Combined (I-squared = 0%, p = 0.7813)
ER-negative
Chinese
Malay
Indian
Combined (I-squared = 31.5%, p = 0.2323)
Fig. 3 Association between standardised PRSs and breast cancer risk in Chinese, Malay and Indian women from Malaysia and Singapore. Odds ratios
(ORs) and AUCs were generated using data from Malaysia Breast Cancer Genetics (MyBrCa) and Singapore Breast Cancer Cohort (SGBCC) studies,
stratified by ethnicity. The squares represent the odds ratios (ORs), the horizontal lines represent the corresponding 95% confidence intervals and the
diamond shapes represent the overall estimates. I-squared and p value (two-sided) for heterogeneity were obtained by fitting a random-effects model and
using generalised Q-statistic estimator (the rma() command in R). The number of cases and controls for each ethnicity by breast cancer subtypes are
tabulated in Table 4. The sample size, ORs and corresponding 95% confidence intervals are also provided in the Source Data file.
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Fig. 4 Association between percentiles of 287-SNP polygenic risk scores
and overall breast cancer risk in Chinese, Malay and Indian women from
Malaysia and Singapore. Results were generated using 5236/5516
Chinese cases/controls, 1084/1332 Malay cases/controls and 580/1018
Indian cases/controls from Malaysia Breast Cancer Genetics (MyBrCa) and
Singapore Breast Cancer Cohort (SGBCC) studies, stratified by ethnicity.
The squares represent the odds ratios (ORs) and the vertical lines
represent the corresponding 95% confidence intervals, with middle quintile
(40–60th) as the reference category. Solid lines represent the observed
ORs and dashed lines represent the predicted ORs of PRS under a
multiplicative polygenic model. Source data are provided in Supplementary
Table 6.
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The 287-SNP PRS had a lower predictive performance for
overall breast cancer among Asians from the three North
American studies, compared to the Asian or European studies
(Table 2). This somewhat surprising observation might be due to
chance, but might reflect a greater admixture with non-Asian
ancestry populations, or a greater variation in the distribution of
lifestyle factors26 leading to a greater variation in risk of breast
cancer. Larger studies of Asian women in non-Asian countries are
needed to provide more reliable estimates.
For subtype analyses using ER-specific PRS, we observed
greater discrimination for ER-positive than ER-negative disease.
This difference was also seen in European studies, and reflects the
fact that the majority of risk SNPs are more strongly associated
with ER-positive than ER-negative disease.
The majority of breast cancer studies have been conducted in
populations of European descent and, as a result, the screening
guidelines for Asian women are often based on those developed
in Europe or North America28,29. In high income countries with
predominantly women of European descent, personalised
screening strategy based on age and PRS rather than age alone
could reduce the number of people eligible for screening30, thus
potentially reducing overdiagnosis, overtreatment and false-
positive diagnoses, which could lead to anxiety and stress in
women who have gone for screening14. In the Asian context,
however, a more cogent argument for stratified screening is to
target limited screening resources on those women most likely to
benefit. Based on the OR estimated in our analyses, and assuming
that a 10-year absolute risk threshold of 2.3% is an appropriate
threshold for screening, the majority of Asian women living in the
Asian country with the highest population risk of breast cancer
(Singapore) would never reach this threshold (Table 5; Supple-
mentary Fig. 2). Notably, only ~25% of Chinese women, ~16% of
Malay women and ~17% of Indian women, would reach this
threshold at any point in their lives. It is important to note,
however, that Asians will experience a substantial increase in
breast cancer incidence over the next decade, and it will therefore
be necessary to revisit the screening recommendations over time.
To explore this, we simulated the 10-year absolute breast cancer
risk of Chinese women using Australian breast cancer inci-
dence31, which is about twice of that in Singapore (Supplemen-
tary Fig. 4). Assuming the breast cancer ORs associated with the
PRS remain similar to those estimated here, those who are in the
60–80th percentile of the risk distribution, which would be
classified as a low-risk group for screening based on current
incidence, would reach the risk threshold for screening at age 45
based on the increased incidences. If the incidence rate reaches
that of Western European countries, a similar proportion of
women (~20%) would not meet screening threshold at any age7.
Our study has some limitations worth noting. Although we
used the largest dataset of Asian women available to date to
evaluate the performance of PRS, the sample size was still too
limited to provide precise relative risk estimates for the extremes
of the PRS distribution, particularly for ER-specific disease. The
majority of the data in the BCAC dataset were generated with
the OncoArray, however, ~27% samples were genotyped using
iCOGS array, which has lower genome-coverage. Of the 287
SNPs, 42 SNPs have imputation score between 0.75 and 0.9, while
53 SNPs have imputation score below 0.75 in the iCOGs dataset.
Table 6 Association between Asian-specific PRSs and overall breast cancer risk.
PRS SNP selection Number of SNPs
published
Number of SNPs
used in analyses
SD controls OR per SD (95% CI) AUC
Low et al.27 Identified in Asian 5 5 0.292 1.25 (1.23–1.27) 0.563
Lee et al.26 Identified in European/Asian 51 51 0.469 1.28 (1.26–1.30) 0.562
Wen et al.15 Identified in European/Asian 44 44 0.400 1.41 (1.39–1.44) 0.586
Hsieh et al.17 Identified in European/Asian 6 6 0.356 1.10 (1.08–1.11) 0.533
Chan et al.19 Identified in European/Asian 46 45a 0.983 1.21 (1.19–1.23) 0.558
Mavaddat et al.7 Identified in European 313 287 0.564b 1.51 (1.22–1.86)b 0.617b
PRSs were constructed using per allele log odds ratios as reported in the literature. As Asian case–control studies genotyped by iCOGs array and 744 samples from MYBRCA batch 1 were used as part of
the development studies in Wen et al. (2016), to avoid upward bias, we restricted these evaluation analyses to Asian cases–controls studies genotyped using the OncoArray and removed overlapping
samples in MYBRCA batch 1.
aOne SNP rs146699004 was not imputed and hence not included in the analyses.
bAnalyses of 287-SNP PRS was repeated using the same dataset as described.
Table 5 Absolute risk of developing overall breast cancer by percentiles.
Chinese Malay Indian
Percentile (%) OR Lifetime risk Agea Lifetime risk Agea Lifetime risk Agea
<1 0.38 0.02 NR 0.02 NR 0.02 NR
1–5 0.48 0.03 NR 0.02 NR 0.02 NR
5–10 0.54 0.03 NR 0.03 NR 0.03 NR
10–20 0.67 0.04 NR 0.03 NR 0.03 NR
20–40 0.83 0.05 NR 0.04 NR 0.04 NR
40–60 1 0.06 NR 0.05 NR 0.05 NR
60–80 1.2 0.07 NR 0.06 NR 0.06 NR
80–90 1.51 0.09 44 0.08 NR 0.07 NR
90–95 1.82 0.11 40 0.09 43 0.09 46
95–99 2.22 0.13 37 0.11 38 0.11 31
>99 2.72 0.16 35 0.13 35 0.13 39
Absolute risks were calculated based on self-declared ethnicity and ethnic-specific incidence and mortality data in Singapore and using 287-SNP PRS relative risk for overall breast cancer. NR never
reached, i.e., the 10-year absolute risk in this percentile never exceed 2.3%.
aAge at which 10-year absolute risk exceeds 2.3%. The 2.3% threshold is the average 10-year absolute risk for a 50 years old woman of European ancestry (50 years old is the recommended age to begin
regular mammographic screening Singapore).
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This may explain in part the evidence for some heterogeneity in
effect sizes between iCOGS and OncoArray datasets. The
attenuation (10%) in the effect size of family history of breast
cancer on breast cancer risk after adjusting for the 287-SNP PRS
is consistent with the predicted contribution of the SNPs to the
twofold familial risk of breast cancer for 287 SNPs (~11%, based
on an overall OR per Asian SD of 1.488). It is important to note,
however, that the estimated association of family history on
breast cancer risk (OR= 1.35) is lower compared with other
studies (OR= 1.8–3.9 in European studies32–34 and OR=
1.52–2.1 in Asian studies16,26). This might be due to inaccuracies
in the family history data. The control women in the largest study
(MyBrCa) contributing to these analyses, accounted for ~30% of
the total data, were recruited through opportunistic screening
which may be enriched for family history relative to the cases.
In addition, there was evidence of heterogeneity (I2= 66.1%,
p value < 0.0001 [chi-squared test]) in the effect sizes of associa-
tion between family history and breast cancer risk across Asian
studies.
In summary, we have shown that a PRS based on common
breast cancer susceptibility variants identified in women of Eur-
opean ancestry is a strong predictor of breast cancer risk in Asian
women. Furthermore, even though Asians are genetically diverse,
our study shows that the PRS derived from women of European
ancestry work equivalently well across the diverse ethnic groups
in Asia. In the meantime, the PRS developed using data from
large European-ancestry studies (providing this is recalibrated to
the Asian population being tested) may be used as the basis for
Asian-specific breast cancer risk prediction models that include
the PRS as well as other predictors of breast cancer risk. These
models will allow for higher levels of risk stratification to be
achieved, as recently demonstrated in women of European
ancestry10. Such risk assessment tools could help in resource
planning, especially in low- and middle-income countries where
resources are limited and population-based screening is unavail-
able, to improve the efficiency of personalised screening.
Methods
Study populations. The study participants were 45,233 women of Asian ancestry
from three sources: (a) 32,238 women (15,755 invasive cases and 16,483 controls)
participating in 10 Asian studies in Breast Cancer Association Consortium
(BCAC); (b) 2719 women (1507 invasive cases and 1212 controls) of Asian
ancestry participating in 3 north American population-based case–control studies
in BCAC; and (c) 10,266 women of Chinese ethnicity participating in Singapore
Chinese Health Study (SCHS32,33). SCHS is a population-based prospective cohort
study. Of the total of 10,255 women aged 43–75 years who had not had any cancer
diagnosis prior to recruitment, 413 registry-confirmed breast cancers developed
over 195,317.2 person years of prospective follow-up. Follow-up started 6 months
after recruitment and was censored at age of breast cancer diagnosis, age at last
known non-breast cancer status, or age on 31 December 2015, whichever came
first. Supplementary Table 1 shows study design and number of breast cancer cases
and controls for individual studies. Comparative results for European women were
obtained from (a) 4926 cases and 4979 controls from 26 population-based
case–control studies participating in BCAC and included in the validation analysis
in Mavaddat et al.7 and (b) ten nested case–control studies within prospective
cohorts in BCAC, comprising 11,225 cases and 17,788 controls, included in the test
dataset in Mavaddat et al.7, but excluding subjects <80 years old and for whom age
was unknown. All studies were approved by the relevant institutional ethics
committees and review boards, and all participants provided written informed
consent.
Genotyping methods. All samples in BCAC studies were genotyped using one of
two arrays: the ~211,155-SNP iCOGS array and the ~533,000-SNP OncoArray34.
Genotype calling, quality control procedure and imputation has been described
previously20,21. Briefly, samples found to be genotypically not female, discordant or
cryptic duplicate pairs, and samples with assay call rate <95% and extreme het-
erozygosity (<5% or >40%, 4.89 SD from the mean for the ethnicity), were
excluded. For first-degree relative pairs, the control was removed from the
case–control pairs; otherwise the sample with the lower call rate was excluded.
SNPs with assay call rate <95% and deviation from Hardy–Weinberg equilibrium
in controls at p < 10−7 in controls or p < 10−12 for cases were excluded. The iCOGS
and OncoArray datasets were imputed separately using a two-stage imputation
approach, using SHAPEIT235 for phasing and IMPUTE236 for imputation, with
1000 Genomes Project (Phase 3) data as the reference panel37.
Samples in the prospective study (SCHS) were genotyped using Illumina Global
Screening Array. Samples with call rate < 95% and extremes in heterozygosity were
excluded. For first- and second-degree relative pairs, the sample with the lower call
rate was excluded. Data were imputed using IMPUTE2 with 1000 Genomes Project
(Phase 3) as reference panel. Only non-monomorphic SNPs in East Asian
population in the reference panel were imputed.
Post-imputation quality was based on the imputation accuracy score
INFOSCORE as provided by IMPUTE236. This metric takes values between 0 and
1, with higher values indicating higher imputation certainty and 1 implying perfect
imputation.
Principal components analyses were used to identify ethnic outliers and define
ancestry informative covariates. For the BCAC data, continental ancestry was
derived by combining the data with the 1000 Genomes Project reference data34.
Individuals with >40% estimated East Asian ancestry were retained. In the second
stage, principal components were generated on the Asian ancestry individuals
using a subset of uncorrelated SNPs. Similar ancestry informative principal
components were generated on the SCHS dataset.
Statistical methods. The analyses were based on the 313-SNP PRS developed in
women of European ancestry7. SNPs with an imputation accuracy score <0.9, based
in the MyBrCa and SGBCC studies, combined, were excluded; to ensure accurate
determination of PRSs in the ethnic-specific analyses.
We derived PRS for overall breast cancer using Eq. (1)
PRSoverall ¼ β1x1 þ β2x2 þ    þ βkxk þ    þ βnxn; ð1Þ
where xk is the dosage of risk allele (0–2) for SNP k and βk is the corresponding
weight. To avoid bias due to overfitting, we used the weights previously derived for
women European ancestry7. The ER-specific PRSs (denoted as PRSER+ for ER-
positive PRS and PRSER− for ER-negative PRS) used same set of SNPs but weights
from the hybrid method as reported in Mavaddat et al.7; the hybrid method assigns
subtype-specific weights to a subset of SNPs for which the effect sizes differ
significantly by subtype. The list of SNPs and the corresponding weight are
provided in Supplementary Data 1. To enable direct comparison of the
performance of each PRS with those reported in European women, we standardised
the PRSs by dividing the PRSs of each individual by the SD) of the PRSs in the
control subjects from the population-based case–control series in European studies.
Logistic regression models were used to estimate ORs for the association
between the standardised PRSs and breast cancer risk. The overall breast cancer
PRS was used as predictor in association analyses between overall breast cancer and
PRS while for subtype-specific analyses, ER-specific PRS were used as predictors.
The PRS were treated as either a continuous or categorical predictor in the model.
When used as a categorical variable, the PRS was categorised into the following
PRS percentile ranges based on the PRS distribution in controls: 1%, 1–5%, 5–10%,
10–20%, 20–40%, 40–60%, 60–80%, 80–90%, 90–95%, 95–99% and 99–100%. The
40–60% category was used as the reference. For ethnic-specific analyses, analyses
were stratified by ethnicity (Chinese, Malay and Indian) using only the MyBrCA
and SGBCC datasets. All models were adjusted for first ten principal components
and study/array/batch; here samples from the same study that were genotyped in
two batches (as was the case for MyBrCa and SGBCC) or on both arrays were
treated as different strata for the purposes of adjustment. A Cox proportional
hazard model was used for the evaluation of the PRS association with overall breast
cancer risk in the prospective cohort and HRs per SD of the PRS were estimated.
The discriminatory accuracy of models for predicting breast cancer risk was
evaluated using the area under the receiver operating characteristic curve (AUC),
adjusted by study. Estimated ORs by PRS quantiles were compared with the
predicted ORs under the model in which the PRS is considered as a continuous
covariate and the log (OR) is linearly related to the PRS. To determine the
proportion of the familial breast cancer risk that could be explained by PRS, we
estimated the OR for the association of first-degree family history and breast cancer
risk first adjusted for first 10 principal components and study/array/batch, and
then additionally adjusted for the PRS.
To evaluate the effect modification of the PRS (as a continuous covariate) by age
and family history of breast cancer in first-degree relatives, we included additional
interaction terms in the logistic regression model.
The predicted proportion of the familial relative risk of breast cancer explained
by the PRS was estimated by noting that the familial relative risk to first degree
relatives of affected individuals due to PRS alone is estimated to be λP ¼ expðγ
2
2 Þ,
where γ is the OR per one SD (equivalent to the SD of the polygenic risk
distribution)38. The proportion of the familial relative risk (on a log scale) due to
the PRS was therefore estimated by using Eq. (2):
lnðλPÞ
ln λð Þ ¼ γ^
2=2lnðλÞ; ð2Þ
where λ is the familial relative risk of breast cancer in first degree relatives, assumed
to be 2 for breast cancer.
To compare the effect sizes of individuals SNPs and breast cancer risk with
those reported in women of European ancestry, we estimated the effect size of the
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association between individual SNP and breast cancer risk in Chinese, Malays and
Indians in MyBrCa and SGBCC studies separately using logistic regression,
adjusting for age, study and the first 10 principal components, assuming a log-
additive genetic model. Intra-class correlation (ICC) was then used to compare the
estimated effect sizes with those reported in Mavaddat et al. (2019)7. To take into
account the sampling error of the effect sizes in the ICC estimate, we fitted a
hierarchical model of the form given by Eq. (3):
yij ¼ βij þ δij; ð3Þ
where yij denotes the parameter estimate of SNP i in population j, βij are the true
parameter estimates and δij  Nð0; σ2ijÞ are the sampling errors, with known SDs
σ ij . The model was fitted by using the expectation–maximisation (EM) algorithm
39
in which βij were estimated using a weighted mean of the observed estimates yij and
the group mean α kð Þi , as given in Eq. (4)
β^ðkÞij ¼
α kð Þi
σ2R
þ yijσ2ij
1
σ2R
þ 1σ2ij
; ð4Þ
in the E-step and the estimated βij were treated as complete data in the M-step to
estimate αðkþ1Þi and σ
2
R , the within-group variance. This process is iterated until the
estimated ICC converged.
The age-specific absolute risks of developing breast cancer, adjusting for
competing mortality, in each PRS percentile was calculated using Eq. (5)
ARg tð Þ ¼
Xt
u¼0
λg uð Þ  SgðuÞ  SmðuÞ; ð5Þ
where λg (u) is the breast cancer incidence associated with PRS at age u, Sg(u) is
the probability of being breast cancer free at age u, and Sm(u) is the probability of
not dying from a cause other than breast cancer to age u. The PRS-specific breast
cancer incidences, λg (u), were calculated iteratively by assuming that the average
age-specific breast cancer incidence over all PRS percentiles agreed with the
population breast cancer incidence6. We calculated lifetime and 10-year absolute
risks using Singaporean mortality and breast cancer incidence for Chinese,
Malays and Indians23,24. The recommended screening age at 50 years old in
many Asian countries is based on European or North American guidelines29 and
the average 10-year risk of breast cancer for women of European ancestry at age
50 years old is 2.3%25. Hence, we determined the proportion of women in the
general population who would have the 10-year risk of breast cancer above this
threshold, using method as described in Pharoah et al.38. To do this, the
maximum 10-year absolute risk, adjusting for competing mortality, for women
age 20–70, was calculated for each PRS centile category (0–0.1%,…, 99.9–100%),
assuming an OR per 1 SD of the PRS of 1.48 (the estimated effect size in Asian
studies).
We compared the predictive performance of the European ancestry-based PRS
with PRSs that were previously developed or evaluated in Asian populations. The
five Asian ancestry-derived PRSs included 5 SNPs15, 51 SNPs17, 44 SNPs19, 6
SNPs26 and 46 SNPs27. The PRSs were derived using Eq. (1) and the corresponding
weights reported in the literature. The list of SNPs and corresponding weights are
tabulated in Supplementary Table 6.
All statistical analyses were conducted using R v.3.0.3 or Stata v.14.2. Logistic
regression and AUC were done using logistic() and comproc() in Stata, Cox
proportional hazard model was done using Coxph() in R.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Summary statistics (OR and confidence limits) for all SNPs used in the analysis are
provided in Supplementary Data 1 of the paper. Request for access to individual level
data on which these analyses were based can be made via the Data Access Coordinating
Committee of BCAC (BCAC Coordinator: BCAC@medschl.cam.ac.uk). The remaining
data are available within the Article, Supplementary Information or available from the
authors upon reasonable request. Source data are provided with this paper.
Received: 19 November 2019; Accepted: 15 July 2020;
References
1. Gøtzsche, P. C., Jørgensen, K. J. Screening for breast cancer with
mammography. Cochrane Database Syst. Rev. 6, CD001877 (2013).
2. Sankaranarayanan, R. et al. Cancer survival in Africa, Asia, and Central
America: a population-based study. Lancet Oncol. 11, 165–173 (2010).
3. Youlden, D. R., Cramb, S. M., Yip, C. H. & Baade, P. D. Incidence and
mortality of female breast cancer in the Asia-Pacific region. Cancer Biol. Med.
11, 101 (2014).
4. Denny, L. et al. Interventions to close the divide for women with breast and
cervical cancer between low-income and middle-income countries and high-
income countries. Lancet 389, 861–870 (2017).
5. Antoniou, A. et al. Average risks of breast and ovarian cancer associated with
BRCA1 or BRCA2 mutations detected in case series unselected for family
history: a combined analysis of 22 studies. Am. J. Hum. Genet. 72, 1117–1130
(2003).
6. Mavaddat, N. et al. Prediction of breast cancer risk based on profiling with
common genetic variants. J. Natl Cancer Inst. 107, djv036 (2015).
7. Mavaddat, N. et al. Polygenic risk scores for prediction of breast cancer and
breast cancer subtypes. Am. J. Hum. Genet. 104, 21–34 (2019).
8. van Veen, E. M. et al. Use of single-nucleotide polymorphisms and
mammographic density plus classic risk factor for breast cancer risk
prediction. JAMA Oncol. 4, 476–482 (2018).
9. Garcia-Closas, M., Gunsoy, N. B., Chatterjee, N. Combined associations of
genetic and environmental risk factors: implications for prevention of breast
cancer. J. Natl Cancer Inst. 106, dju305 (2014).
10. Lee, A. et al. BOADICEA: a comprehensive breast cancer risk prediction
model incorporating genetic and non-genetic risk factors. Genet. Med.
(2019).
11. Eklund, M. et al. The WISDOM Personalized Breast Cancer Screening Trial:
simulation study to assess potential bias and analytic approaches. JNCI Cancer
Spectr. 2, pky067 (2019).
12. Gagnon, J. et al. Recommendations on breast cancer screening and prevention
in the context of implementing risk stratification: impending changes to
current policies. Curr. Oncol. 23, e615 (2016).
13. Unicancer. MyPeBS: Personalising Breast Screening (2019).
14. Pashayan, N., Morris, S., Gilbert, F. J. & Pharoah, P. D. Cost-effectiveness and
benefit-to-harm ratio of risk-stratified screening for breast cancer: a life-table
model. JAMA Oncol. 4, 1504–1510 (2018).
15. Wen, W. et al. Prediction of breast cancer risk based on common genetic
variants in women of East Asian ancestry. Breast Cancer Res. 18, 124 (2016).
16. Zheng, W. et al. Genetic and clinical predictors for breast cancer risk
assessment and stratification among Chinese women. J. Natl Cancer Inst. 102,
972–981 (2010).
17. Hsieh, Y.-C. et al. A polygenic risk score for breast cancer risk in a Taiwanese
population. Breast Cancer Res. Treat. 163, 131–138 (2017).
18. Sueta, A. et al. A genetic risk predictor for breast cancer using a combination
of low-penetrance polymorphisms in a Japanese population. Breast Cancer
Res. Treat. 132, 711–721 (2012).
19. Chan, C. H. T. et al. Evaluation of three polygenic risk score models for the
prediction of breast cancer risk in Singapore Chinese. Oncotarget 9, 12796
(2018).
20. Michailidou, K. et al. Association analysis identifies 65 new breast cancer risk
loci. Nature 551, 92 (2017).
21. Michailidou, K. et al. Large-scale genotyping identifies 41 new loci associated
with breast cancer risk. Nat. Genet. 45, 353 (2013).
22. Liu, X., Saw, W.-Y., Ali, M., Ong, R. T.-H. & Teo, Y.-Y. Evaluating the
possibility of detecting evidence of positive selection across Asia with sparse
genotype data from the HUGO Pan-Asian SNP Consortium. BMC Genomics
15, 332 (2014).
23. International Agency for Research on Cancer. Cancer Incidence in Five
Continents Volumns I to X (2018).
24. Government of Singapore. Age-Specific Death Rates, Annual. (2017).
25. DeSantis, C., Ma, J., Bryan, L. & Jemal, A. Breast cancer statistics, 2013. Cancer
J. Clin. 64, 52–62 (2014).
26. Lee, C. P. et al. Breast cancer risk assessment using genetic variants and risk
factors in a Singapore Chinese population. Breast Cancer Res. 16, R64 (2014).
27. Low, S. K. et al. Genome-wide association study of breast cancer in the
Japanese population. PLoS ONE 8, e76463 (2013).
28. Bhoo-Pathy, N. et al. Breast cancer research in Asia: adopt or adapt Western
knowledge? Eur. J. Cancer 49, 703–709 (2013).
29. US Preventive Services Task Force. Screening for breast cancer: US Preventive
Services Task Force recommendation statement. Ann. Intern. Med. 151, 716
(2009).
30. Chowdhury, S. et al. Incorporating genomics into breast and prostate cancer
screening: assessing the implications. Genet. Med. 15, 423 (2013).
31. Australian Institute of Health and Welfare. Incidence of breast cancer. Breast
Cancer in Australia: An Overview (Australian Government, 2012).
32. Hankin, J. H. et al. Singapore Chinese Health Study: development, validation,
and calibration of the quantitative food frequency questionnaire. Nutr. Cancer
39, 187–195 (2001).
33. Wu, A. H., Koh, W. P., Wang, R., Lee, H. P. & Yu, M. C. Soy intake and breast
cancer risk in Singapore Chinese Health Study. Br. J. Cancer 99, 196–200
(2008).
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-17680-w ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:3833 | https://doi.org/10.1038/s41467-020-17680-w |www.nature.com/naturecommunications 9
34. Amos, C. I. et al. The OncoArray Consortium: a network for understanding
the genetic architecture of common cancers. Cancer Epidemiol. Prev. Biomark.
26, 126–135 (2017).
35. Delaneau, O., Marchini, J. & Zagury, J.-F. A linear complexity phasing method
for thousands of genomes. Nat. Methods 9, 179 (2012).
36. Howie, B. N., Donnelly, P. & Marchini, J. A flexible and accurate genotype
imputation method for the next generation of genome-wide association
studies. PLoS Genet. 5, e1000529 (2009).
37. The International Genome Sample Resource (IGSR). 1000 Genomes Release
(Phase 3) (2018).
38. Pharoah, P. D. et al. Polygenic susceptibility to breast cancer and implications
for prevention. Nat. Genet. 31, 33–36 (2002).
39. Dempster, A. P., Laird, N. M. & Rubin, D. B. Maximum Likelihood from
Incomplete Data via the EM Algorithm. J. R. Stat. Soc., Series B. 29, 1–37 (1977).
Acknowledgements
This study was supported by grants from Newton-Ungku Omar Fund [grant No. MR/
P012930/1] and Wellcome Trust [grant No. v203477/Z/16/Z]. The Malaysian Breast
Cancer Genetic Study was established using funds from the Malaysian Ministry of Sci-
ence, and the Malaysian Ministry of Higher Education High Impact Research Grant
[grant No. UM.C/HIR/MOHE/06]. The Malaysian Mammographic Density Study was
established using funds raised through the Sime Darby LPGA tournament and the High
Impact Research Grant. Additional funding was received from Yayasan Sime Darby,
PETRONAS, Estee Lauder Group of Companies and other donors of Cancer Research
Malaysia. SGBCC is funded by NUS Start Up Grant, National University Cancer Institute
Singapore (NCIS) Centre Grant, NMRC Clinical Scientist Award, NMRC Clinician
Scientist Award-Senior Investigator, Asian Breast Cancer Research Fund and Breast
Cancer Prevention Programme under Saw Swee Hock School of Public Health.
Recruitment of controls were funded by the Biomedical Research Council (05/1/21/19/
425). W.K.H. is the recipient of L’Oreal-UNESCO For Women in Science National
Fellowship. J.L. is the recipient of a National Research Foundation Singapore Fellowship
(NRF-NRFF2017-02). A.C.A. is supported through Cancer Research—UK (C12292/
A20861). J.S. holds a Canada Research Chair in Oncogenetics. The PERSPECTIVE I&I
project is funded by the Government of Canada through Genome Canada and the
Canadian Institutes of Health Research, the Ministère de l’Économie et de l’Innovation
du Québec through Genome Québec, the Quebec Breast Cancer Foundation, the CHU de
Quebec Foundation and the Ontario Research Fund. Genotyping of the OncoArray was
principally funded from three sources: the PERSPECTIVE project, funded by the Gov-
ernment of Canada through Genome Canada and the Canadian Institutes of Health
Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’
through Genome Québec, and the Quebec Breast Cancer Foundation; the NCI Genetic
Associations and Mechanisms in Oncology (GAME-ON) initiative and Discovery,
Biology and Risk of Inherited Variants in Breast Cancer (DRIVE) project (NIH Grants
U19 CA148065 and X01HG007492); and Cancer Research UK (C1287/A10118 and
C1287/A16563). BCAC is funded by Cancer Research UK (C1287/A16563), by the
Caucasian Community’s Seventh Framework Programme under grant agreement 223175
(HEALTH-F2-2009-223175) (COGS) and by the Caucasian Union’s Horizon 2020
Research and Innovation Programme under grant agreements 633784 (B-CAST) and
634935 (BRIDGES). Combining of the GWAS data were supported in part by The
National Institute of Health (NIH) Cancer Post-Cancer GWAS initiative grant U19 CA
148065 (DRIVE, part of the GAME-ON initiative). For MyBrCa, we want to thank Pui-
Yoke Kwan, Sean Wen, Norhashimah Hassan, Peter Choon-Eng Kang, In-Nee Kang,
Kah-Nyin Lai, Hanis Hasmad, Jin-Tong Ng, Gaik-Theng Toh, Nancy Geen-See Tan,
Suhaida Selamat, Nancy Geen-See Tan, Rohaya Mohd Kasim, Malkit Kaur Dhillon,
Thin-Chai Liu, Ernie Azwa, Hanani Che Halim, Leelavathy Krishnan, Don-Na Tan,
Sweet-Lin Goh, Nur Naquiah Kamaruddin, Faridah Bakri, the participants of this study,
and all staff at Cancer Research Malaysia, University Malaya, and Sime Darby Medical
Centre who assisted in recruitment and interviews. For SGBCC, we want to thank the
programme manager Jenny Liu, clinical research coordinators/research assistants Siok-
Hoon Yeo, Kimberley Chua, Ting-Ting Koh, Amanda Ong, Jin-Yee Lee, Michelle Mok,
Ying-Jia Chew, Jing-Jing Hong and Hui-Min Lau for their contributions in recruitment
and Alexis Khang for processing the DNA samples. We also want to thank all the
participants’ support to SGBCC. There are additional funding and acknowledgements
listed in Supplementary Note 1.
Author contributions
Study design: W.K.H., N.M., J. Simard, D.F.E., S.H.T. and A.C.A.; writing group: W.K.H.,
M.M.T., N.M., M.C.T., J.L, D.F.E., S.H.T. and A.C.A.; data management: M.M.T., M.K.B.
and Q.W.; bioinformatic analysis: J.D., J.P.T. and K. Michailidou; Statistical analysis:
W.K.H., N.M, M.M.T., M.C.T., S.M., P.J.H. and D.F.E.; provided DNA samples and/or
phenotypic data: S.M., J.L., D.K., J.Y.C., S.J., X.O.S., S.Y.Y., S.K.P., S.W.K., C.Y.S., J.C.Y.,
E.Y.T., P.M.Y.C., K. Muir, A.L., A.H.W., D.O.S., K. Matsuo, H.I., C.W.C., J.N., W.S.Y.,
S.H.L., G.H.L., A.K., T.L.C., S.M.T., J. Seah, E.M.J., A.W.K., W.P.K., C.C.K., M.I., T.Y.,
K.M.V.T., K.T.B.T., J.J.S., K.J.A, S.N.H., K.R., A.V., X.S., P.D.P.P., W.Z., A.M.D.,
J. Simard, R.M.v.D., C.H.Y., N.A.M.T., M.H. and S.H.T. All authors read and approved
the final version of the paper.
Competing interests
The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41467-
020-17680-w.
Correspondence and requests for materials should be addressed to W.-K.H. or S.-H.T.
Peer review information Nature Communications thanks the anonymous reviewer(s) for
their contribution to the peer review of this work. Peer reviewer reports are available.
Reprints and permission information is available at http://www.nature.com/reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2020
Weang-Kee Ho 1,2✉, Min-Min Tan 1,2, Nasim Mavaddat3, Mei-Chee Tai2, Shivaani Mariapun1,2,
Jingmei Li 4,5, Peh-Joo Ho 4, Joe Dennis 3, Jonathan P. Tyrer 6, Manjeet K. Bolla3, Kyriaki Michailidou3,7,8,
Qin Wang3, Daehee Kang9,10,11, Ji-Yeob Choi10,11, Suniza Jamaris12, Xiao-Ou Shu13, Sook-Yee Yoon2,
Sue K. Park 9,10,11, Sung-Won Kim14, Chen-Yang Shen15,16, Jyh-Cherng Yu17, Ern Yu Tan18,
Patrick Mun Yew Chan18, Kenneth Muir 19, Artitaya Lophatananon19, Anna H. Wu20, Daniel O. Stram 20,
Keitaro Matsuo 21,22, Hidemi Ito 21,22, Ching Wan Chan 23,24, Joanne Ngeow25,26, Wei Sean Yong27,
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-17680-w
10 NATURE COMMUNICATIONS |         (2020) 11:3833 | https://doi.org/10.1038/s41467-020-17680-w |www.nature.com/naturecommunications
Swee Ho Lim28, Geok Hoon Lim 28, Ava Kwong29,30,31, Tsun L. Chan29,32, Su Ming Tan33, Jaime Seah33,
Esther M. John34, Allison W. Kurian 34,35, Woon-Puay Koh36,37, Chiea Chuen Khor 4, Motoki Iwasaki38,
Taiki Yamaji38, Kiak Mien Veronique Tan27,39, Kiat Tee Benita Tan27,39, John J. Spinelli40,41,
Kristan J. Aronson42, Siti Norhidayu Hasan2, Kartini Rahmat 43, Anushya Vijayananthan43, Xueling Sim 37,
Paul D. P. Pharoah 3,44, Wei Zheng13, Alison M. Dunning 44, Jacques Simard 45,
Rob Martinus van Dam37,46, Cheng-Har Yip 47, Nur Aishah Mohd Taib12, Mikael Hartman5,
Douglas F. Easton 3,44,48, Soo-Hwang Teo 2,12,48✉ & Antonis C. Antoniou3,48
1School of Mathematical Sciences, Faculty of Science and Engineering, University of Nottingham Malaysia, Jalan Broga, Semenyih 43500 Selangor,
Malaysia. 2Cancer Research Malaysia, 1 Jalan SS12/1A, Subang Jaya 47500 Selangor, Malaysia. 3Centre for Cancer Genetic Epidemiology,
Department of Public Health and Primary Care, University of Cambridge, CB1 8RN, Cambridge, UK. 4Human Genetics, Genome Institute of
Singapore, 60 Biopolis St, 138672 Singapore, Singapore. 5Department of Surgery, National University Hospital and NUHS, 1E Kent Ridge Road,
119228 Singapore, Singapore. 6Strangeways Research Laboratory, University of Cambridge, 2 Worts’ Causeway, Cambridge, UK. 7Biostatistics Unit,
The Cyprus Institute of Neurology & Genetics, 6 Iroon Avenue, 2371 Ayios, Dometios, Cyprus. 8Cyprus School of Molecular Medicine, The Cyprus
Institute of Neurology & Genetics, 6 Iroon Avenue, 2371 Ayios, Dometios, Cyprus. 9Department of Preventive Medicine, Seoul National University
College of Medicine, 103 Daehak-Ro, Jongno-Gu, 03080 Seoul, Korea. 10Department of Biomedical Sciences, Seoul National University Graduate
School, 103 Daehak-Ro, Jongno-Gu, 03080, Seoul, Korea. 11Cancer Research Institute, Seoul National University, 103 Daehak-Ro, Jongno-Gu, Seoul
03080, Korea. 12Department of Surgery, Faculty of Medicine, University of Malaya, Jalan Universiti, 50630 Kuala Lumpur, Malaysia. 13Division of
Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of
Medicine, 1161 21st Ave S # D3300, Nashville, TN 37232, USA. 14Department of Surgery, Daerim Saint Mary’s Hospital, 657 Siheung-Daero,
Daerim-Dong, Yeongdeungpo-Gu, 07442 Seoul, Korea. 15Institute of Biomedical Sciences, Academia Sinica, 115128, Section 2, Academia Road,
Taipei, Taiwan. 16School of Public Health, China Medical University, Taichung, Taiwan. 17Department of Surgery, Tri-Service General Hospital, Taipei
114, Taiwan. 18Department of General Surgery, Tan Tock Seng Hospital, Singapore 308433, Singapore. 19Division of Population Health, Health
Services Research and Primary Care, School of Health Sciences, The University of Manchester, Oxford Road, M13 9PL, Manchester, UK.
20Department of Preventive Medicine, Keck School of Medicine, University of Southern California, 1975 Zonal Ave, Los Angeles 90033 CA, USA.
21Division of Cancer Epidemiology and Prevention, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-Ku, 464-8681 Nagoya, Japan.
22Division of Cancer Epidemiology, Nagoya University Graduate School of Medicine, 65 Tsurumai-Cho, Showa-Ku, 466-8550 Nagoya, Japan.
23Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, 117597 Singapore, Singapore. 24National University
Hospital, National University Health System, Singapore, Singapore. 25Division of Medical Oncology, National Cancer Centre Singapore, 11 Hospital
Drive, 169610 Singapore, Singapore. 26Oncology Academic Clinical Program, Duke-NUS Graduate Medical School, 8 College Road, 169857
Singapore, Singapore. 27Division of Surgical Oncology, National Cancer Centre, Singapore, Singapore. 28Breast Department, KK Women’s and
Children’s Hospital, Singapore100 Bukit Timah Road, 229899, Singapore. 29Hong Kong Hereditary Breast Cancer Family Registry, Cancer Genetics
Centre, 18A Kung Ngam Village Road, Happy Valley, Hong Kong. 30Department of Surgery, The University of Hong Kong, 102 Pokfulam Road, Pok
Fu Lam, Hong Kong. 31Department of Surgery, Hong Kong Sanatorium and Hospital, 2 Village Rd, Happy Valley, Hong Kong. 32Department of
Pathology, Hong Kong Sanatorium and Hospital, 2 Village Rd, Happy Valley, Hong Kong. 33General Surgery, Changi General Hospital,
Singapore, Singapore. 34Department of Medicine, Division of Oncology, Stanford Cancer Institute, Stanford University School of Medicine, 780
Welch Road, Suite CJ250C, Stanford 94304 CA, USA. 35Department of Health Research and Policy—Epidemiology, Stanford University School of
Medicine, 259 Campus Drive, Stanford 94305 CA, USA. 36Health Services and Systems Research, Duke-NUS Medical School, Stanford University
School of Medicine, 8 College Road, 169857 Singapore, Singapore. 37Saw Swee Hock School of Public Health, National University of Singapore and
National University Health System, 12 Science Drive 2, #10-01, 117549 Singapore, Singapore. 38Division of Epidemiology, Center for Public Health
Sciences, National Cancer Center, 5-1-1 Tsukiji, Chuo-Ku, 104-0045 Tokyo, Japan. 39Department of General Surgery, Singapore General Hospital,
Singapore, Singapore. 40Population Oncology, BC Cancer, 675 West 10th Avenue, VancouverV5Z 1G1 BCCanada. 41School of Population and Public
Health, University of British Columbia, 2329 West Mall VancouverV6T 1Z4 BCCanada. 42Department of Public Health Sciences, and Cancer
Research Institute, Queen’s University, 10 Stuart Street, Kingston K7L 3N6 ON, Canada. 43Biomedical Imaging Department, Faculty of Medicine,
University of Malaya, Kuala Lumpur, Malaysia. 44Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, 2
Worts’ Causeway, CB1 8RN, Cambridge, UK. 45Genomics Center, CHU de Québec-Université Laval Research 2705 Blvd Laurier Québec (Québec)
G1V 4G2, Quebec, Canada. 46Departments of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
47Sime Darby Medical Centre, 1 Jalan SS12/1A, Subang Jaya 47500 Selangor, Malaysia. 48These authors contributed equally: Douglas F. Easton,
Soo-Hwang Teo, Antonis C. Antoniou. ✉email: weangkee.ho@nottingham.edu.my; soohwang.teo@cancerresearch.my
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-17680-w ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:3833 | https://doi.org/10.1038/s41467-020-17680-w |www.nature.com/naturecommunications 11
